Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Company Profile
- CEO
- Erik Emerson
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 15
- Beta
- 0.62
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -186.31
Financials
Revenue
$0.00-100.0%Net Income
$-3.81MEBITDA
$-3.79MFree Cash Flow
$-3.62MEPS (diluted)
$-11.40Shares Outstanding (diluted)
222.2K+2916.9%Operating Expenses
$3.40MCash & Debt
$1.12MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-19.39M | $-323.40 |
| 2024 | $0.00 | $-22.60M | $-911.40 |
| 2023 | $0.00 | $-7.10M | $-574.50 |
| 2022 | $0.00 | $-4.43M | $-429.90 |
| 2021 | $0.00 | $-4.07M | $-394.80 |
| 2020 | $0.00 | $-2.70M | $-268.20 |
| 2019 | $208.0K | $-3.52M | $-442.50 |
| 2018 | $43.5K | $-6.72M | $0.00 |
| 2017 | $589.5K | $-10.33M | $0.00 |
| 2016 | $611.7K | $-5.41M | $0.00 |
| 2015 | $143.2K | $-5.84M | $0.00 |
| 2014 | $59.8K | $2.98M | $0.00 |
| 2013 | $0.00 | $-9.80M | $-1897.20 |
| 2012 | $0.00 | $-2.77M | $-101.70 |
Valuation
GCTKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (2)
- Newsbenzinga.com·6h ago·Neutral
Why GlucoTrack Shares Are Trading Higher By Around 118%; Here Are 20 Stocks Moving Premarket Shares of GlucoTrack Inc (NASDAQ:GCTK) rose sharply in pre-market trading following the announcement that its subsidiary, Lokahi Therapeutics, signed its first external, fee-for-service partnership.
View source ↗ - Newsbusinesswire.com·13d ago·Positive
Glucotrack Announces $11.5 Million Financing RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)-- #Glucotrack--Glucotrack announces $11.5M convertible note financing, including new capital and note rollover, to support strategic growth.
View source ↗
Insider trading
Open-market buys and sells by GCTK officers and directors.
- Bought
- $25.3m
- Sold
- —
10 trades
0 trades
- John A. Ballantyne Revocable Living Trust Dated 08/01/2017bought
- John A. Ballantyne Revocable Living Trust Dated 08/01/2017bought
- John A. Ballantyne Revocable Living Trust Dated 08/01/2017bought
- Ballantyne Johnbought
- Ballantyne Johnbought
- Ballantyne Johnbought
- Goode Paulbought
- Sycoff Drewbought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GCTK.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.